ReviewArthritis and rheumatism2012
Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.
Review in Arthritis and rheumatism, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Clinical rheumatology · 2016Pooled it
- Risk of serious infections, myocardial infarction or stroke, venous thromboembolic events, and malignancy in patients with psoriatic arthritis treated with tofacitinib compared with biologic treatments in the United States.Arthritis research & therapy · 2026Article
- Urologic malignancy risk with chronic tumor necrosis factor-alpha inhibitor (TNF-I) exposure: a multicenter, retrospective cohort study.World journal of urology · 2026Article
- Age-Specific Risk Factors for Cancer in a Long-Term Korean Cohort of Patients with Ankylosing Spondylitis Treated with TNF Inhibitors.Journal of clinical medicine · 2025Article
- Long-term risk of de novo malignancy with tumor necrosis factor alpha (TNF) inhibitor immunosuppression: a multicenter, retrospective cohort study.Journal of inflammation (London, England) · 2025Article
- Managing Cardiovascular and Cancer Risk Associated with JAK Inhibitors.Drug safety · 2023Review
- JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.Annals of the rheumatic diseases · 2023Article
- TNF-α induces endothelial-mesenchymal transition promoting stromal development of pancreatic adenocarcinoma.Cell death & disease · 2021Article
- TNF in the era of immune checkpoint inhibitors: friend or foe?Nature reviews. Rheumatology · 2021Review
- Management of inflammatory rheumatic conditions in the elderly.Rheumatology (Oxford, England) · 2019Review
- Resolution of Gastric Cancer-Promoting Inflammation: A Novel Strategy for Anti-cancer Therapy.Current topics in microbiology and immunology · 2019Review
- Tumor necrosis factor-alpha inhibitors and risk of non-Hodgkin lymphoma in a cohort of adults with rheumatologic conditions.International journal of cancer · 2018Article
- Human Papillomavirus-Induced Cancer: Late Relapse in a Patient Treated With Tumor Necrosis Factor-Alpha Inhibitor.Journal of global oncology · 2017Article
- Factors associated with fractures in HIV-infected persons: which factors matter?Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2017Article
- Rheumatoid arthritis - an update for general dental practitioners.British dental journal · 2016Article
- Risk of malignancy in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under immunosuppressive therapy: a single-center experience.Internal and emergency medicine · 2016Observational
- Article
- Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study.Clinical rheumatology · 2015Observational
- In vivo maturation of allo-specific CD8 CTL and prevention of lupus-like graft-versus-host disease is critically dependent on T cell signaling through the TNF p75 receptor but not the TNF p55 receptor.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.